Evidence map›Paper›PMID 39844769›Full record

ArticleHaematologica2025

Sodium-glucose co-transporter-2 inhibitor treatmentassociated changes in hemoglobin level in anemic patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.

Ali Alsugair, Saubia Fathima, Fnu Aperna, Naseema Gangat, Ayalew Tefferi

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07516847 (A Phase II, Prospective, Open-Label Study to Evaluate the Efficacy and Safety of Dapagliflozin for Anemia in Patients With Lower-Risk Myelodysplastic Syndromes), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07516847 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

A Phase II, Prospective, Open-Label Study to Evaluate the Efficacy and Safety of Dapagliflozin for Anemia in Patients With Lower-Risk Myelodysplastic Syndromes

TypeinterventionalSponsorSeug yun Yoon, MDRan2026 to 2029Enrolled37ConditionsMyelodysplastic Syndromes (MDS), AnemiaArmsDapagliflozin (10mg Tab)
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ali AlsugairDivision of Hematology, Mayo Clinic, Rochester, Minnesota.
Saubia FathimaDivision of Hematology, Mayo Clinic, Rochester, Minnesota.
Fnu ApernaDivision of Hematology, Mayo Clinic, Rochester, Minnesota.
Naseema GangatDivision of Hematology, Mayo Clinic, Rochester, Minnesota.
Ayalew TefferiDivision of Hematology, Mayo Clinic, Rochester, Minnesota. tefferi.ayalew@mayo.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39844769
PMCPMC12130756

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.